shizhang wei

Dr. shizhang wei


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLisheng Chen
Lisheng Chen
SWshizhang wei
shizhang wei
YHYong He
Yong He
XWXin Wang
Xin Wang
THTingting He
Tingting He
YZYanling Zhao
Yanling Zhao
Chronic gastritis (CG) is a common clinical digestive system disease, which is not easyily cured and is prone to recurrence. Traditional Chinese medicine (TCM) plays a significant role in the treatment of CG and has attracted increasing attention for clinical applications. In recent years, a large number of reports have shown that TCM has good therapeutic effect on CG. The aim of this paper is to investigate the pharmacological activities and mechanism of action of TCM in the treatment of CAG. Therefore, by searching the databases of Pubmed, China National Knowledge Infrastructure, Wanfang, and Baidu academic databases, this paper has summarized the molecular mechanisms of TCM in improving CG. The results show that the improvement of GC by TCM is closely related to a variety of molecular mechanisms, including the inhibition of Helicobacter pylori (Hp) infection, alleviation of oxidative stress, improvement of gastric function, repair of gastric mucosa, inhibition of inflammatory response, and apoptosis. More importantly, IRF8-IFN-γ, IL-4-STAT6, Hedgehog, pERK1/2, MAPK, PI3K-Akt, NF-κB, TNFR-c-Src-ERK1/2-c-Fos, Nrf2/HO-1, and HIF-1α/VEGF signaling pathways are considered as important molecular targets for TCM in the treatment of GC. These important findings will provide a direction and a basis for further exploring the pathogenesis of GC and tapping the potential of TCM in clinical treatment. This review also puts forward a bright prospect for future research of TCM in the treatment of CG.

22 November 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LCLisheng Chen
Lisheng Chen
LCLei Chang
Lei Chang
WWWenbin Wu
Wenbin Wu
MJManyi Jing
Manyi Jing
HLHaotian Li
Haotian Li
YZYanling Zhao
Yanling Zhao

6 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LCLisheng Chen
Lisheng Chen
XWXin Wang
Xin Wang
JLJianyu Li
Jianyu Li
LZLijuan Zhang
Lijuan Zhang
WWWenbin Wu
Wenbin Wu
YZYanling Zhao
Yanling Zhao
Background: Berberine (BBR) is widely used to treat gastrointestinal diseases. However, the pharmacological mechanism of action of BBR in anti-chronic atrophic gastritis (CAG) remains unclear. This study aimed to investigate the mechanism of action of BBR in CAG by integration of molecular biology and multi-omics studies strategy.Methods: The CAG model was established by alternating drinking water of 0.1% ammonia and 20 mmol/L sodium deoxycholate, accompanied by an irregular diet. Serum biochemical indices including PGI, PGII, GAS-17, IL-6, IL-1β, and TNF-α were analyzed. HE and AB-PAS staining were employed to assess pathological damage in gastric tissue. The underlying molecular mechanism of BBR in CAG treatment was explored via the integration of network pharmacology, transcriptomics, widely targeted metabolomics and intestinal flora analysis. Finally, relevant key targets and pathway were verified.Results: The results showed that BBR exerted therapeutic effects in improving CAG via alleviating inflammation response, maintaining the gastric mucosal barrier’s integrity and repairing gastric mucosal tissues. Network pharmacology showed that the treatment of CAG by BBR mainly involved in inflammatory response, apoptosis, angiogenesis and metabolic processes. Furthermore, 234 different expression genes were identified in the gastric tissue transcriptome, which were mainly involved in biological processes such as cell adhesion, angiogenesis, apoptosis, cell migration and lipids metabolism by regulating the MAPK signaling pathway. Metabolomics results showed that 125 differential metabolites were also identified, while the pathways were mainly involved in D-glutamine and D-glutamate metabolism, and tyrosine metabolism, etc. Integrating transcriptomics and metabolomics analyses indicated that BBR directly regulated Carnitine C3:0, LPC (0:0/20:3), L-Glutamic Acid and FFA (15:0) by acting on SLC25A20, PNLIPRP1, PLA2G4C, GSR, GFPT2, GCLM, CTPS1, ACSL1, ACOT4 and ACOT2. 16S rRNA sequencing revealed that BBR could restore the balance of gut microbiota dysbiosis by significantly regulating the relative abundance of unclassified_Muribaculaceae and Lactobacillus_johnsonii.Conclusion: This study demonstrated that BBR alleviates CAG through the regulation of the MAPK signaling pathway, metabolic disorders and gut microbiota dysbiosis, thereby revealing the complex mechanism of BBR in relation to alleviating CAG from multiple levels and perspectives.

18 June 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
HZHongying Zhou
Hongying Zhou
XMXiao Ma
Xiao Ma
XZXuelin Zhou
Xuelin Zhou
SWshizhang wei
shizhang wei
CLChunyu Li
Chunyu Li
Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease with an increasing incidence. The complex pathogenesis of AIH poses significant challenges for clinical treatment. In recent years, with the introduction of cutting-edge concepts such as “immune–metabolic interplay” and “intercellular communication networks,” along with novel detection methods and technologies, research on the pathogenesis of AIH has shifted from a single-molecular-mechanism perspective to a systematic regulatory network analysis. This shift has not only provided more research evidence for a deeper understanding of the molecular biological mechanisms underlying AIH but also offers a potential reference for the development of targeted therapeutic drugs for AIH based on novel targets. Therefore, this review starts with aberrant activation signals from key immune cells—including dendritic cells (DCs), macrophages (Mφ), and T/B cells—and integrates the intercellular signaling communication mechanisms between hepatocytes, cholangiocytes, and immune cells to systematically summarize the key molecular biological mechanisms and targets identified in recent years, providing a reference for future elucidation of the critical mechanisms of AIH. On this basis, the review further integrates the current application and research progress of clinically used AIH therapeutic drugs, as well as those at various stages of development, including potential therapeutic compounds. It discusses the limitations of current clinical drugs and evaluates the feasibility and future application potential of potential compounds for AIH treatment in preclinical and clinical studies, thereby offering comprehensive research evidence for the management of AIH.